Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 … Next › Last »

Prevision Policy Clips | FDA Deputy Commissioner For Operations/COO Is DoD Veteran Barclay Butler

March 25, 2025

Prevision Policy Clips | White Oak U-Turn: Senate HELP General Counsel Barrett Tenbarge To Remain With Committee, No Longer Headed To FDA

March 24, 2025

A Glow Up For VAERS? Rebranding Vaccine Safety Systems With More Robust, Community-Level Data Could Address Vaccine Hesitancy, Gottlieb Says

March 21, 2025

Prevision Policy Clips | “Most Favored Nation” Drug Pricing Options Outlined By GOP Think Tank

March 21, 2025

Vaccine Uptake Depends On “Compelling Evidence,” Not “Mandates,” FDA’s Marks Says; Planning Ahead May Make It Easier To Measure Indirect Benefits To Encourage Adoption

March 20, 2025

Prevision Policy Clips | Oz Faces GOP Stumbling Block On Road To CMS: Missouri Republican Sen. Hawley

March 20, 2025

Prevision Policy Clips | FTC Down To Two Commissioners After Trump “Fires” Democratic Commissioners

March 19, 2025

Prevision Policy Clips | “Newly Proposed” Benefits Is Focus Of ICER/NICE/Canada Drug Agency Working Group

March 18, 2025

Office Of Therapeutic Products Attempting To Weather Staff Cuts: “We’re Going To Do Our Best,” CBER Director Marks Says

March 17, 2025

Prevision Policy Clips | Return-To-Office Day For FDA: Expect Disruptions

March 17, 2025

CMS Nominee Oz Delivers Wizardly Performance In Confirmation Hearing; Drug Pricing Is Not Major Focus, But Oz Pledges To Use Price Negotiation, Support Sickle Cell Demo

March 14, 2025

Prevision Policy Clips | Flu Strain Selections Announced By FDA After Internal Meeting

March 14, 2025

FDA Rare Disease “Case Studies” Illustrate Dose Optimization (Sanofi’s Xenpozyme) And Single Trial Efficacy Standard (Sentynyl’s Nulibry)

March 13, 2025

FDA Commissioner Nominee Makary Clears Committee After Chief Counsel Departs; CDC Nominee Weldon Withdrawn By White House

March 13, 2025

Prevision Policy Clips | FDA Reverses Course On Chief Counsel Ahead Of Makary Confirmation Vote: Hilary Perkins “Has Resigned

March 13, 2025

FDA Gene & Cell Therapy Office Leadership Ranks Are Thinning Fast: Office of Clinical Evaluation Director Fashoyin-Aje, Cell Therapy CMC Head Lombardi Are Latest Departures

March 12, 2025

Prevision Policy Clips | FDA Chief Counsel Will Be Hilary Perkins After HHS Reorganizes

March 12, 2025

Makary’s Team Takes Shape: FDA Deputy For Legislation Is Former Hill Staffer With User Fee/21CC Experience Graham; Chief Of Staff Is Traficant

March 11, 2025

Flat-Line Funding Is Best Case For FDA Heading Into Shutdown Uncertainty, Return-To-Office Deadlines; Pediatric PRV Still In Limbo

March 11, 2025

Prevision Policy Clips | FDA Medical Reviewers, Manufacturing Inspectors Not Eligible for HHS “Buyout”

March 11, 2025

Prevision Policy Clips | CMS Nominee Oz Set For Confirmation Hearing March 14

March 10, 2025

ICER Panel Endorses Value Of Vertex’ Journavx Compared To Opioids, But Questions Benefits Compared To NSAIDs; Coverage Policies Will Be Key To Uptake

March 7, 2025

Prevision Policy Clips | FDA Commissioner Nominee Makary Breezes Through Senate Hearing

March 7, 2025

VRBPAC Will Be Back, But Maybe Not For Flu, FDA Commissioner Nominee Makary Says; Is Another Advisory Committee Reset Coming?

March 7, 2025

Generics, Biosimilars – And OTCs – Are Part Of FDA Role In Drug Pricing Policy, Commissioner Nominee Makary Says

March 6, 2025
1 2 3 4 5 … Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Copyright © 2025 Prevision Policy. All Rights Reserved. Privacy Policy